Moderna, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2020 to Q1 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Moderna, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q1 2022.
  • Moderna, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2022 was -$146M, a 192% decline year-over-year.
  • Moderna, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $901K.
  • Moderna, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$578M.
  • Moderna, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$296M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2022 -$146M -$96M -192% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-04
Q1 2021 -$50M -$50M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.